Apoxis receives FDA Orphan Medicinal Product designation for treatment of XLHED
APO200 is a protein therapeutic based on Apoxis' multimerization technology and is currently in preclinical development. XLHED (X-linked hypohidrotic ectodermal dysplasia) is a rare genetic and potentially life threatening disease. Patients affected by the disease cannot control their body temperature through sweating, and sudden infant death in relation to hyperthermia has been reported. Infants also frequently suffer from respiratory tract infections, due to the absence of mucous glands in the respiratory tract, and these can result in sudden death. Other symptoms include a lack of normal hair, and abnormal development of mouth and teeth. APO200 is expected to enter human studies in 2007 following further preclinical studies.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.